PureTech Health says US FDA progress provides clear path for LYT-200

PureTech Health received FDA fast track designation for its blood cancer drug LYT-200 and concluded a positive end-of-phase one meeting, clearing a path to phase 2 clinical trials.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.